Rituximab in Patients with Inflammatory Myopathies

Seong Wook Kang

doi:10.4078/jrd.2013.20.6.345

Journal List > J Rheum Dis > v.20(6) > 1064075

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kang: Rituximab in Patients with Inflammatory Myopathies

Editorial

J Rheum Dis 2013;20(6):345-347.

Published online: 31 December 2013

DOI: https://doi.org/10.4078/jrd.2013.20.6.345

Rituximab in Patients with Inflammatory Myopathies

Seong Wook Kang

Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea

Corresponding to : Seong Wook Kang, Department of Internal Medicine, Chungnam National University School of Medicine, 282, Munhwa-ro, Jung-gu, Daejeon 301-721, Korea. E-mail : kangsw@cnuh.co.kr

Received 29 November 2013 Accepted 12 December 2013

This is a Free Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

1. Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012; 8:CD003643.

2. Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011; 70:427–36.

3. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64:1215–26.

4. Yang JA, Lee SJ, Park JW, Kwon HM, Moon JY, Ko DJ, et al. Rituximab treatment for the patients with refractory inflammatory myopathy. J Rheum Dis. 2013; 20:303–9.

5. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001; 40:1262–73.

6. Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al. Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011; 38:1436–40.

7. Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford). 2011; 50:2206–13.

8. Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. RIM Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, place-bo-phase trial. Arthritis Rheum. 2013; 65:314–24.

9. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005; 52:601–7.

10. Cuttner J, Spiera H, Gorevic P. Rituximab in refractory and relapsed dermatomyositis and polymyositis: comment on the article by Oddis et al. Arthritis Rheum. 2013; 65:2497–8.

TOOLS

Similar articles